Role of inflammation in neurodegenerative diseases

Perry, 2002, Atypical inflammation in the central nervous system in prion disease, Curr Opin Neurol, 15, 349, 10.1097/00019052-200206000-00020

Perry, 2004, The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease, Brain Behav Immun, 18, 407, 10.1016/j.bbi.2004.01.004

Forman, 2004, Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs, Nat Med, 10, 1055, 10.1038/nm1113

McGeer, 2001, Inflammation, autotoxicity and Alzheimer disease, Neurobiol Aging, 22, 799, 10.1016/S0197-4580(01)00289-5

Mrak, 2005, Glia and their cytokines in progression of neurodegeneration, Neurobiol Aging, 26, 349, 10.1016/j.neurobiolaging.2004.05.010

McGeer, 2004, Inflammation and the degenerative diseases of aging, Ann N Y Acad Sci, 1035, 104, 10.1196/annals.1332.007

Rainero, 2004, Association between the interleukin-1alpha gene and Alzheimer's disease: a meta-analysis, Neurobiol Aging, 25, 1293, 10.1016/j.neurobiolaging.2004.02.011

Licastro, 2004, A polymorphism of the interleukin-1 beta gene at position +3953 influences progression and neuro-pathological hallmarks of Alzheimer's disease, Neurobiol Aging, 25, 1017, 10.1016/j.neurobiolaging.2003.11.002

Hayes, 2004, A polymorphic variation in the interleukin 1A gene increases brain microglial cell activity in Alzheimer's disease, J Neurol Neurosurg Psychiatry, 75, 1475, 10.1136/jnnp.2003.030866

Bellucci, 2004, Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein, Am J Pathol, 165, 1643, 10.1016/S0002-9440(10)63421-9

Bugiani, 1999, Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau, J Neuropathol Exp Neurol, 58, 667, 10.1097/00005072-199906000-00011

Akiyama, 2000, Inflammation and Alzheimer's disease, Neurobiol Aging, 21, 383, 10.1016/S0197-4580(00)00124-X

Zhang, 2004, Metabolite-initiated protein misfolding may trigger Alzheimer's disease, Proc Natl Acad Sci USA, 101, 4752, 10.1073/pnas.0400924101

Crisby, 2004, Effects of high cholesterol diet on gliosis in apolipoprotein E knockout mice. Implications for Alzheimer's disease and stroke, Neurosci Lett, 369, 87, 10.1016/j.neulet.2004.05.057

Minghetti, 1998, Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide, Prog Neurobiol, 54, 99, 10.1016/S0301-0082(97)00052-X

West, 2002, Endotoxin tolerance: a review, Crit Care Med, 30, S64, 10.1097/00003246-200201001-00009

Mosser, 2003, The many faces of macrophage activation, J Leukoc Biol, 73, 209, 10.1189/jlb.0602325

Ajmone-Cat, 2003, Prolonged exposure of microglia to lipopolysaccharide modifies the intracellular signaling pathways and selectively promotes prostaglandin E2 synthesis, J Neurochem, 87, 1193, 10.1046/j.1471-4159.2003.02087.x

Fassbender, 2004, The LPS receptor (CD14) links innate immunity with Alzheimer's disease, FASEB J, 18, 203, 10.1096/fj.03-0364fje

Ferrari, 2004, Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain, Am J Pathol, 165, 1827, 10.1016/S0002-9440(10)63438-4

Polazzi, 2002, Reciprocal interactions between microglia and neurons: from survival to neuropathology, Rev Neurosci, 13, 21, 10.1515/REVNEURO.2002.13.3.221

De Simone, 2003, Apoptotic PC12 cells exposing phosphatidylserine promote the production of anti-inflammatory and neuroprotective molecules by microglial cells, Neuropathol Exp Neurol, 62, 208, 10.1093/jnen/62.2.208

Henson, 2001, The phosphatidylserine receptor: a crucial molecular switch?, Nat Rev Mol Cell Biol, 2, 627, 10.1038/35085094

De Simone, 2004, Atypical antiinflammatory activation of microglia induced by apoptotic neurons: possible role of phosphatidylserine-phosphatidylserine receptor interaction, Mol Neurobiol, 29, 197, 10.1385/MN:29:2:197

Li, 2003, Phosphatidylserine receptor is required for clearance of apoptotic cells, Science, 302, 1560, 10.1126/science.1087621

Dudal, 2004, Inflammation occurs early during the Abeta deposition process in TgCRND8 mice, Neurobiol Aging, 25, 861, 10.1016/j.neurobiolaging.2003.08.008

Schwab, 2004, Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease, Exp Neurol, 188, 52, 10.1016/j.expneurol.2004.03.016

Herrup, 2004, Divide and die: cell cycle events as triggers of nerve cell death, J Neurosci, 24, 9232, 10.1523/JNEUROSCI.3347-04.2004

Minghetti, 2004, Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases, J Neuropathol Exp Neurol, 63, 901, 10.1093/jnen/63.9.901

Depino, 2003, Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease, Eur J Neurosci, 18, 2731, 10.1111/j.1460-9568.2003.03014.x

Combrinck, 2002, Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease, Neuroscience, 112, 7, 10.1016/S0306-4522(02)00030-1

Holmes, 2003, Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease, J Neurol Neurosurg Psychiatry, 74, 788, 10.1136/jnnp.74.6.788

Tracey, 2002, The inflammatory reflex, Nature, 420, 853, 10.1038/nature01321

Borovikova, 2000, Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin, Nature, 405, 458, 10.1038/35013070

Wang, 2003, Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation, Nature, 421, 384, 10.1038/nature01339

Shytle, 2004, Cholinergic modulation of microglial activation by α7 nicotinic receptors, J Neurochem, 89, 337, 10.1046/j.1471-4159.2004.02347.x

De Simone, 2005, Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures, J Neuroinflammation, 2, 4, 10.1186/1742-2094-2-4

Banerjee, 2000, Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease: a stereological approach, Neurobiol Dis, 7, 666, 10.1006/nbdi.2000.0317

Reid, 2000, Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease, Neurobiol Aging, 21, 741, 10.1016/S0197-4580(00)00168-8

Wilkinson, 2004, Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy, Drugs Aging, 21, 453, 10.2165/00002512-200421070-00004

Hellstrom-Lindahl, 2004, Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice, Eur J Neurosci, 19, 2703, 10.1111/j.0953-816X.2004.03377.x

Marien, 2004, Noradrenergic mechanisms in neurodegenerative diseases: a theory, Brain Res Brain Res Rev, 45, 38, 10.1016/j.brainresrev.2004.02.002

Heneka, 2003, Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression, J Neurochem, 85, 387, 10.1046/j.1471-4159.2003.01694.x

Galea, 2003, Intrinsic regulation of brain inflammatory responses, Cell Mol Neurobiol, 23, 625, 10.1023/A:1025084415833

McGeer, 1992, Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease, Neurology, 42, 447, 10.1212/WNL.42.2.447

Aisen, 2002, The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease, Lancet Neurol, 1, 279, 10.1016/S1474-4422(02)00133-3

in t’ Veld, 2001, Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease, N Engl J Med, 345, 1515, 10.1056/NEJMoa010178

Aisen, 2003, Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial, JAMA, 289, 2819, 10.1001/jama.289.21.2819

Reines, 2004, Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study, Neurology, 62, 66, 10.1212/WNL.62.1.66

Gasparini, 2004, Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action, J Neurochem, 91, 521, 10.1111/j.1471-4159.2004.02743.x

Sastre, 2003, Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase, J Neurosci, 23, 9796, 10.1523/JNEUROSCI.23-30-09796.2003

Camacho, 2004, Peroxisome proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide, J Neurosci, 24, 10908, 10.1523/JNEUROSCI.3987-04.2004

Zhou, 2003, Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho, Science, 302, 1215, 10.1126/science.1090154

Lleo, 2004, Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation, Nat Med, 10, 1065, 10.1038/nm1112

Chen, 2003, Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease, Arch Neurol, 60, 1059, 10.1001/archneur.60.8.1059

Asanuma, 2004, Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases, Curr Pharm Des, 10, 695, 10.2174/1381612043453072

Teismann, 2003, Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration, Proc Natl Acad Sci USA, 100, 5473, 10.1073/pnas.0837397100

Hunot, 2004, JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease, Proc Natl Acad Sci USA, 101, 665, 10.1073/pnas.0307453101

Hastings, 1995, Enzymatic oxidation of dopamine: the role of prostaglandin H synthase, J Neurochem, 64, 919, 10.1046/j.1471-4159.1995.64020919.x

Przybylkowski, 2004, Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse, Brain Res, 1019, 144, 10.1016/j.brainres.2004.05.095

Blum, 2004, Clinical potential of minocycline for neurodegenerative disorders, Neurobiol Dis, 17, 359, 10.1016/j.nbd.2004.07.012

Ciesielski-Treska, 2004, Fibrillar prion peptide (106–126) and scrapie prion protein hamper phagocytosis in microglia, Glia, 46, 101, 10.1002/glia.10363

Gelinas, 2004, Immunotherapy for Alzheimer's disease, Proc Natl Acad Sci USA, 101, 14657, 10.1073/pnas.0404866101

Sadowski, 2004, Vaccines for conformational disorders, Expert Rev Vaccines, 3, 279, 10.1586/14760584.3.3.279

Wilcock, 2004, Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage, J Neuroinflammation, 1, 24, 10.1186/1742-2094-1-24

Ferrer, 2004, Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease, Brain Pathol, 14, 11, 10.1111/j.1750-3639.2004.tb00493.x

Racke, 2005, Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta, J Neurosci, 25, 629, 10.1523/JNEUROSCI.4337-04.2005

Barger, 2005, Vascular consequences of passive Abeta immunization for Alzheimer's disease. Is avoidance of ‘malactivation’ of microglia enough?, J Neuroinflammation, 2, 2, 10.1186/1742-2094-2-2

Jantzen, 2002, Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice, J Neurosci, 22, 2246, 10.1523/JNEUROSCI.22-06-02246.2002

Bi, 2004, Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia, J Biol Chem, 279, 48238, 10.1074/jbc.M405442200